The costs of publication of this article were defrayed in part by the payment of page charges. The article must therefore be hereby marked "*advertisement*" in accordance with 18 U.S.C. Section 1734 solely to indicate this fact.

[identifying the genetic variants]{.smallcaps} that increase the risk of high blood pressure may help optimize preventive strategies, primarily because this information could be used to target high-risk individuals for early treatment and helps elucidate the biological underpinnings of the disease. An important part of this process is to undertake appropriately designed confirmation studies to determine the robustness of previously reported associations. One method to achieve this is to undertake meta-analyses of published and unpublished data.

Since its initial reported association with Type 2 diabetes ([@r7]), a common missense variant at exon 8 of the peroxisome proliferator activated receptor-γ coactivator 1α (*PPARGC1A)* gene has been repeatedly associated with type 2 diabetes ([@r4]) and with related traits, including obesity ([@r19]), dyslipidemia ([@r9]), aerobic fitness ([@r15]), and insulin resistance ([@r16]). In those studies, the minor Ser482 allele is typically associated with increased susceptibility to disease. However, in several large studies that assessed the association between Gly482Ser and hypertension, the Ser482 allele conferred a protective effect ([@r2], [@r17]).

The protein encoded by the *PPARGC1A* gene coactivates at least 30 transcription factors involved in various aspects of cellular energy metabolism ([@r22]). The gene is expressed in tissues with high metabolic activity, such as heart, liver, kidney, and brown adipose, and could play a role in the regulation of blood pressure by interacting with mineralocorticoid and estrogen receptors ([@r17]) or through reactive oxygen species detoxification ([@r23]).

The objective of the present study was to assess, using conventional meta-analysis and meta-regression techniques, the relationships between the Gly482Ser variant at *PPARGC1A* and measures of blood pressure and hypertension risk in published and unpublished material from 17 studies comprising 13,949 individuals. We also assessed the putative effect-modifying roles of age, sex, and body mass index (BMI) on the genotype-blood pressure relationships.

MATERIALS AND METHODS
=====================

Selection of Studies for Meta-Analysis
--------------------------------------

All of the studies published before April 2007 were identified by extended computer-based searches of PubMed databases. The following search terms were used: ("peroxisome proliferator activator receptor gamma coactivator 1" or "*PPARGC1A"* or "PGC-1" or "PGC-1alpha" or "PGC1alpha") and "polymorphism" and ("hypertension" or "blood pressure"). The retrieved studies were then read in their entirety to assess their appropriateness for inclusion in the meta-analysis. All studies that tested the Gly482Ser polymorphism for association with blood pressure/hypertension were included in this meta-analysis. All of the references cited in the studies were also reviewed to identify additional published work not indexed by PubMed. Only studies in humans that have used validated genotyping methods were considered. Data from these studies were collated for meta-analysis, and, where necessary, the authors of the original paper were contacted to obtain the original data. We were unable to obtain the necessary data in all cases, because the corresponding author either did not respond to the request for data, or declined to provide access to all necessary original data ([@r5], [@r6], [@r17], [@r18]). Previously unpublished materials were included from four studies: three of which comprised white middle-aged adults from the UK, and the fourth comprised adult Pima Indians. The details of these studies are provided below.

Previously Unpublished Material
-------------------------------

*1*) In the Medical Research Council (MRC) Ely study, 694 individuals with the necessary clinical data were genotyped from a population-based sampling frame from and around the city of Ely in Cambridgeshire, UK. The genetic ([@r3]) and clinical aspects ([@r8]) of the study have been described in detail previously. In brief, blood pressure was measured using an Accutorr automated sphygmomanometer (Datascope, Cambridge, UK) three times at 1-min intervals. The average of the three measurements was used in analyses. Height and weight were assessed using standard methods. A sample of fasting blood was drawn, and DNA was extracted from white blood cells.

*2*) In Cambridgeshire Type 2 diabetes Case-Control Study (CCCS), 507 individuals from the control group and 514 individuals from the case group of the CCCS underwent a standard clinical examination at Addenbrookes Hospital, Cambridge, UK. The genetic ([@r3]) and clinical aspects ([@r12]) of the study have been described in detail previously. In brief, systolic (SBP) and diastolic blood pressures (DBP) were measured using an Accutorr automated sphygmomanometer (Datascope, Cambridge, UK) on the right arm with the participant in the supine position. A sample of fasting blood was drawn, and DNA was extracted from white blood cells.

*3*) The European Prospective Investigation of Cancer (EPIC) Obesity case-cohort study is nested within the EPIC-Norfolk Study, a population-based cohort study of 25,663 Europid men and women, aged 40--79 yr, recruited in Norfolk, UK. The cases (*n* = 1,111 participants) were randomly selected from the obese individuals within this cohort and are defined as those with a BMI \> 30 kg/m^2^. The control-cohort consists of 2,128 individuals randomly selected from the EPIC-Norfolk study, excluding those from the case group. All participants attended a clinic visit where height, weight, and waist circumference were measured using standard anthropometric techniques.

*4*) In the National Institutes of Health (NIH) Longitudinal Study of Pima Indians, 1,088 adult American Indians, primarily of Pima or Tohonto O\'odam ancestry, in whom the necessary genetic and clinical data were available, were included in this study. The genetic ([@r16]) and clinical aspects ([@r10]) of the study have been described in detail previously. In brief, height and weight were measured with a rigid stadiometer and calibrated scales. SBP and DBP were measured in the supine position and on the right arm with an appropriately sized cuff for arm circumference. Blood pressures were recorded with a mercury gauge sphygmomanometer to the nearest 2 mmHg at the first and fourth Korotkoff sounds, respectively.

All participants provided written, informed consent, and ethical permission was granted by the local research ethics committees for all of the above-mentioned studies.

Statistical Analysis
--------------------

### Meta-analysis.

Two types of analyses were carried out for the meta-analysis of association between the sodium nitroprusside (SNP) and blood pressure traits. In the initial analyses, we obtained raw data, including age and sex, from 11 studies and tested for the interaction between the SNP and sex in each study and in the combined meta-analysis data set using generalized linear regression models. The means of blood pressures were adjusted for age and sex. We then meta-analyzed the data, including the five studies for which raw data were not available. To do this, we first simulated data points in these five studies without raw data using the mean and SD from each study and each genotype. A meta-analysis (ANOVA) was then undertaken combining the 5 simulated data sets and the 11 raw data sets. A random-effects generalized linear model was used if the heterogeneity statistic among studies was statistically significant; otherwise, a fixed-effects model was used. After all 10,000 simulations, the mean of the 10,000 meta-analysis *P* values was used to infer the final overall level of statistical significance. Hypertension was defined as ≥140 mmHg for SBPs or ≥90 mmHg for DBPs. The use of anti-hypertensive drug treatment for the definition of hypertension varied across studies. For the continuous trait models, individuals receiving blood pressure medication were excluded (*n* = 1,041). A meta-analysis for hypertension (a case-control meta-analysis) was performed where data permitted (in 12 studies). Owing to the absence of specific data on measurement methods in some studies and methodological restrictions in modeling these differences, we did not specifically account for measurement difference in these analyses. However, the stratified analyses performed here, combined with the random-effects meta-analysis method, control somewhat for heterogeneous measurement methods across studies. All analyses were undertaken in Stata/SE 9.2 for Windows (StataCorp LP). Power calculations were performed using the Quanto V1.1.1 software ([@r14]). The significance threshold was set at *P* \< 0.05.

RESULTS
=======

The sample size used in these analyses yields \>95% power (α = 0.01) to detect a per allele association of at least 0.6 and 0.4 mmHg for SBP and DBP, respectively. The effect estimates are consistent with those previously reported in the Gly482Ser association studies on hypertension or blood pressure.

[Table 1](#t1){ref-type="table"} shows the clinical characteristics of the study participants included from published and unpublished studies for the meta-analysis. In brief, the MRC Ely study comprised, on average, middle-aged overweight white men and women (∼58% female) with normal glucose control. The CCCS comprised overweight late middle-aged men and women (∼36% female) from Cambridgeshire in the UK, with or without Type 2 diabetes. The EPIC obesity case-cohort study comprised white late middle-aged men and women from the Eastern region of the UK. The NIH longitudinal study included young adult American Indians (∼55% female) from the Gila River Indian Reserve in southern Arizona, many of whom were overweight or obese ([@r10]).

In the pooled data set, the genotype distribution of the Gly482Ser polymorphism was 0.47, 0.42, and 0.11 for Gly482Gly, Gly482Ser, and Ser482Ser genotypes, respectively.

In the meta-analysis, the adjusted associations between Gly482Ser and blood pressure were found to be inverse (DBP: β = −0.13 mmHg per copy of the Ser482 allele, *P* = 0.333; SBP: β = −0.27 mmHg per copy of the Ser482 allele, *P* = 0.329), but were not statistically significant. The Gly482Ser variant was not associated with hypertension ([Table 2](#t2){ref-type="table"}), the overall odds ratio was 0.97, and the 95% confidence interval was 0.87--1.08 (*P* = 0.585; [Fig. 1](#f1){ref-type="fig"}). The interactions between the SNP and sex from the 11 studies ([Tables 3](#t3){ref-type="table"} and [4](#t4){ref-type="table"}) were not statistically significant (SBP: *P* = 0.966; DBP: *P* = 0.715).

We observed significant between-study heterogeneity for both SBP (*P* = 0.003) and DBP (*P* = 0.021), which was attributable to three of the cohorts \[Danish whites ([@r2]) (*study 5*), UK whites (CCCS cases), and Pima Indians\]. Excluding these studies from the meta-analysis resolved the between-study heterogeneity, but the associations between the Gly482Ser genotype and SBP or DBP remained nonsignificant (data not shown).

Ethnic-Specific Analyses
------------------------

To reduce the possibility that our results were confounded by population stratification, we undertook subanalyses in whites only. In these models, we found no evidence of association for any blood pressure trait ([Tables 2](#t2){ref-type="table"}--[4](#t4){ref-type="table"}).

Interaction Analyses
--------------------

Previous studies have suggested that the effects of *PPARGC1A* may be modified by age, sex, or obesity. Therefore, we tested genotype interaction terms for age, sex, and BMI. The results of these analyses are shown in [Tables 3](#t3){ref-type="table"} and [4](#t4){ref-type="table"}. We found no evidence of genotype interactions with sex or BMI. However, within the entire collection of cohorts, we observed a highly statistically significant interaction between genotype and age on DBP (*P* \< 0.0001), and a nominal statistical interaction between genotype and age on SBP (*P* = 0.026). We proceeded by stratifying the data sets by below (*n* = 2,511) and above (*n* = 5,088) age 50 yr and repeating the main effects models. In these analyses, strong genotype associations were evident for SBP \[Gly482Gly: 121.4 (120.4, 122.5), Gly482Ser: 125.9 (124.6, 127.1), Ser482Ser: 129.2 (126.5, 131.9), *P* = 7.20 × 10^−12^\] and DBP \[Gly482Gly: 73.5 (72.8, 74.2), Gly482Ser: 77.0 (76.2, 77.8), Ser482Ser: 79.1 (77.4, 80.9), *P* = 4.20 × 10^−12^\] in younger individuals, and no statistical association was evident in older individuals \[SBP: Gly482Gly: 139.9 (139.1, 140.7), Gly482Ser: 139.6 (138.8, 140.4), Ser482Ser: 139.2 (137.7, 140.8), *P* = 0.41; DBP: Gly482Gly: 84.7 (84.1, 85.2), Gly482Ser: 84.4 (83.8, 84.9), Ser482Ser: 84.5 (83.5, 85.5), *P* = 0.51\] ([Fig. 2](#f2){ref-type="fig"}). When these analyses were repeated in whites only, the interaction terms were no longer statistically significant, which may reflect lower power or confounding by population stratification.

DISCUSSION
==========

In European whites, a significant inverse association between the Ser482 allele and hypertension risk has been reported ([@r2], [@r17]). By contrast, the Ser482 allele was associated with an increased risk of hypertension in French men ([@r6]) and in Argentinean adolescents ([@r21]), and no statistically significant association was evident in Chinese ([@r5]), Asian Indians ([@r24]), or in Danish whites with the metabolic syndrome ([@r1]). To clarify the nature of the relationship between the *PPARGC1A* Gly482Ser genotype and blood pressure, we undertook a meta-analysis of 13,949 individuals.

Our study included more than 6,000 previously unreported observations and was sufficiently powered to detect effects of lesser magnitude than those previously reported. In our study, we did not observe direct evidence of association between the Gly482Ser genotype and measures of blood pressure. However, a robust statistical gene-age interaction was observed for DBP, and a nominal statistical interaction was observed for SBP, suggesting that the effect of Gly482Ser on blood pressure diminishes with age. It is possible that these observations represent interactions between the *PPARGC1A* gene and factors associated with younger age, which may include physical activity, a factor that biologically interacts with *PPARGC1A* ([@r11]). It is also possible that genetic effects are more evident at younger ages, owing to the accumulative exposure to environmental risk factors for high blood pressure with age. Alternatively, it may be that cohort effects influence the association of Gly482Ser with blood pressure. Finally, it is possible that survivor bias or treatment effect may inhibit the detection of genetic effects in older individuals.

It is important to highlight that, when the gene × age interaction analyses were conducted in whites only, no statistical evidence of interaction was observed; this may reflect the lower level of statistical power in this subgroup or that the gene-age interaction was attributable to population stratification. The latter is a type of confounding that can occur when genetic associations are tested in pooled samples of diverse ethnic groups. Confounding by population stratification can emerge when disease frequencies differ substantially between ethnic groups, and the genotype being studied is associated with ethnicity. It is possible in this scenario that an apparent association between genotype and the disease is attributable purely to confounding by ethnicity. Thus some prior reports of association between Gly482Ser and hypertension may be limited by this factor. The meta-analytic approach differs from conventional tests of genetic association because the point estimates are first calculated within each subgroup before being combined. By consequence, confounding by population stratification is less likely in a meta-analysis than in a conventional pooled-sample analysis. Thus it is plausible that the absence of an interaction effect in the present study when excluding non-whites from the analyses is due to reduced statistical power rather than confounding by ethnic factors.

Despite moderate-to-high heritability estimates for blood pressure, the recently published genomewide scans have failed to detect, with any degree of robustness, genetic risk factors for this trait ([@r26]). This suggests that, although blood pressure is no doubt under genetic control, the specific nature of the trait and/or the way it is assessed in epidemiological studies has seriously hindered the elucidation of the trait\'s genetic mechanisms. The methodological factors that may impede the detection of genetic associations with blood pressure are many. For example, high blood pressure is a commonly treated condition; if people carrying the Gly482 allele are truly more likely to have elevated blood pressure, these people will also be more likely to be treated for the condition. The differential blood pressure treatment by Gly482Ser genotype would reduce the magnitude of the association between genotype and blood pressure. Furthermore, blood pressure is a highly biologically variable trait and is hence prone to regression dilution, a feature that inherently limits statistical power to detect genetic associations with this trait ([@r13]). It is also worth considering that the publications reporting the results from two studies that found significant associations between Gly482Ser and hypertension ([@r18], [@r25]) did not include sufficient continuous trait data for those studies to be included in the blood pressure meta-analysis. Thus we cannot be certain that, with the inclusion of data from those studies, the results would remain the same. A further key consideration, which is supported by the significant gene-age interactions in this study, is that interactions between genetic and environmental factors inhibit the detection of genetic effects on blood pressure.

This is the largest study to date examining the association between the Gly482Ser genotype and blood pressure. Our analyses suggest that Gly482Ser may be associated with blood pressure in younger but not older individuals, such that Ser482 allele homozygotes have DBP and SBP roughly 5 and 9 mmHg higher, respectively, than Gly482 allele homozygotes. These observations contrast the findings of several recent blood pressure studies but are consistent with studies of this locus in relation to other metabolic traits. The recently published results from genomewide association studies have revealed no convincing genetic risk factors for high blood pressure ([@r26]). This contrasts the successful detection of genetic risk factors for many other complex disease traits ([@r26]). Animal functional studies and human heritability studies suggest that blood pressure is under genetic control. Therefore, it is likely that studies that are specifically designed to overcome the limitations inherent in blood pressure research will be necessary if the genetic basis of this disease trait is to be elucidated.
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![The horizontal axis shows odds ratio estimates with the corresponding 95% confidence interval (CI) for the Gly482Ser allele and the risk of hypertension (*n* = 9,861). The 95% CIs of pooled estimates are displayed as a horizontal line through the dots. \**Studies 1*, *3*, *4*, and *5* correspond to the study numbers mentioned in the paper by Franks et al. ([@r8]). T2D, Type 2 diabetes; MRC, Medical Research Council; CCCS, Cambridgeshire Type 2 diabetes Case Control Study; EPIC, European Prospective Investigation of Cancer.](zdg0080880180001){#f1}
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###### 

Characteristics of the study participants used in the meta-analysis

  Cohort                                                                                        *n* (Male/Female)   Age, yr         BMI, kg/m^2^   SBP, mmHg        DBP, mmHg       Genotype Frequency (*n*)   Genotype Proportion, %   MAF, %
  --------------------------------------------------------------------------------------------- ------------------- --------------- -------------- ---------------- --------------- -------------------------- ------------------------ --------
  Danish whites                                                                                                                                                                                                                         
      *Study 1* (Ref. [@r8])[\*](#t1fn1){ref-type="table-fn"}[†](#t1fn2){ref-type="table-fn"}   459/554             57.23 (7.08)    25.9 (3.98)    133.12 (17.98)   84.07 (10.86)   454/442/117                44.8/43.6/11.6           33.4
      *Study 3* (Ref. [@r8])[\*](#t1fn1){ref-type="table-fn"}[†](#t1fn2){ref-type="table-fn"}   75/82               65.87 (5.12)    25.22 (3.82)   134.75 (19.09)   77.65 (11.23)   63/69/25                   40.1/44.0/15.9           37.9
      *Study 4* (Ref. [@r8])[\*](#t1fn1){ref-type="table-fn"}[†](#t1fn2){ref-type="table-fn"}   430/268             59.3 (9.65)     29.3 (5.04)    158.28 (23.38)   95.14 (13.93)   281/316/101                40.2/45.3/14.5           37.1
      *Study 5* (Ref. [@r8])[\*](#t1fn1){ref-type="table-fn"}[†](#t1fn2){ref-type="table-fn"}   256/216             46.53 (12.38)   24.26 (3.08)   134.44 (19.12)   76.57 (9.81)    212/195/65                 44.9/41.3/13.8           34.4
  UK whites                                                                                                                                                                                                                             
      MRC Ely[†](#t1fn2){ref-type="table-fn"}                                                   285/409             54.55 (10.3)    26.41 (4.06)   126.65 (16.59)   76.41 (10.83)   269/341/84                 38.8/49.1/12.1           36.7
      CCCS cases[†](#t1fn2){ref-type="table-fn"}                                                328/186             63.56 (7.82)    29.71 (5.22)   144.49 (17.05)   86.53 (10.67)   230/226/58                 44.7/44/11.3             33.3
      CCCS controls[†](#t1fn2){ref-type="table-fn"}                                             324/183             63.85 (7.83)    27.27 (4.14)   138.41 (17.68)   84.93 (11.23)   211/215/81                 41.6/42.4/16             37.2
  Pima Indians[†](#t1fn2){ref-type="table-fn"}                                                  495/593             20.73 (13.9)    25.66 (8.21)   116.26 (20.4)    68.16 (14.53)   735/318/35                 67.6/29.2/3.2            17.8
  French Canadians (Ref. [@r2])[†](#t1fn2){ref-type="table-fn"}                                 77/189              42.4 (10.15)    52.83 (9.98)   142.66 (18.71)   86.13 (11.87)   105/122/39                 39.5/45.9/14.6           37.6
  EPIC                                                                                                                                                                                                                                  
      Obese[†](#t1fn2){ref-type="table-fn"}                                                     484/627             59.43 (8.77)    32.90 (2.87)   140.93 (17.3)    86.45 (11.25)   480/492/139                43.2/44.3/12.5           34.7
      Cohort[†](#t1fn2){ref-type="table-fn"}                                                    995/1,133           58.96 (8.94)    26.57 (4.01)   135.76 (17.56)   82.73 (10.8)    932/960/236                43.8/45.1/11.1           33.6
  Asian Indians                                                                                                                                                                                                                         
      Cases (Ref. [@r3])[‡](#t1fn3){ref-type="table-fn"}                                        238/329             50.0 (12.0)     25.1 (4.2)     128.0 (18.0)     77.0 (11.0)     303/212/52                 53.4/37.4/9.2            27.9
      Control (Ref. [@r3])[‡](#t1fn3){ref-type="table-fn"}                                      399/576             44.0 (13.0)     23.2 (4.4)     120.0 (17.0)     75.0 (10.0)     534/360/81                 54.8/36.9/8.3            26.8
  Danish whites (Ref. [@r4])[‡](#t1fn3){ref-type="table-fn"}                                    1,108/1,147                         24.48 (4.27)                                    931/1036/288               41.3/45.9/12.8           35.7

Values are unadjusted means (SD); *n* = 12,455 subjects. An additional 1,504 individuals, in whom quantitative trait data for blood pressure and body mass index (BMI) were collected, were also included in the hypertension meta-analysis. SBP, systolic blood pressure; DBP, diastolic blood pressure; MAF, minor allele frequency; CCCS, Cambridgeshire Type 2 diabetes Case-Control Study; MRC, Medical Research Council; EPIC, European Prospective Investigation of Cancer.

*Studies 1*, *3*, *4*, and *5* correspond to the study numbers mentioned in the paper.

Studies with raw data.

Studies from published paper. Mean, SD, and ANOVA *P* values were obtained from published papers or from authors.

###### 

The distribution of Gly482Ser genotypes in people with and without hypertension, and odds ratios and heterogeneity results for the hypertension analyses

  Cohort                                                                                        Genotype Frequencies   OR    95% CI   *P* Value                                    
  --------------------------------------------------------------------------------------------- ---------------------- ----- -------- ----------- ----- ----- ------ ------ ------ -------
  Danish whites                                                                                                                                                                    
      *Study 1* (Ref. [@r8])[\*](#t2fn1){ref-type="table-fn"}[†](#t2fn2){ref-type="table-fn"}   242                    253   73       212         189   44    0.84   0.70   1.01   0.061
      *Study 3* (Ref. [@r8])[\*](#t2fn1){ref-type="table-fn"}[†](#t2fn2){ref-type="table-fn"}   33                     47    13       30          22    12    0.88   0.56   1.38   0.565
      *Study 4* (Ref. [@r8])[\*](#t2fn1){ref-type="table-fn"}[†](#t2fn2){ref-type="table-fn"}   45                     42    20       236         274   81    0.94   0.70   1.27   0.694
      *Study 5* (Ref. [@r8])[\*](#t2fn1){ref-type="table-fn"}[†](#t2fn2){ref-type="table-fn"}   127                    121   38       85          74    27    1.00   0.77   1.30   0.992
  Pima Indians[†](#t2fn2){ref-type="table-fn"}                                                  641                    272   29       94          46    6     1.17   0.86   1.59   0.331
  UK whites                                                                                                                                                                        
      MRC Ely[†](#t2fn2){ref-type="table-fn"}                                                   184                    251   68       85          90    16    0.66   0.47   0.92   0.013
      CCCS cases[†](#t2fn2){ref-type="table-fn"}                                                66                     79    21       164         147   37    0.81   0.62   1.07   0.138
      CCCS controls[†](#t2fn2){ref-type="table-fn"}                                             102                    104   31       109         111   50    1.17   0.92   1.50   0.203
  French Canadians (Ref. [@r2])[†](#t2fn2){ref-type="table-fn"}                                 30                     31    5        75          91    34    1.46   0.96   2.21   0.079
  EPIC                                                                                                                                                                             
      Obese[†](#t2fn2){ref-type="table-fn"}                                                     180                    163   44       300         329   95    1.16   0.97   1.39   0.111
      Cohort[†](#t2fn2){ref-type="table-fn"}                                                    490                    482   119      442         478   117   1.06   0.93   1.21   0.355
  Austrian whites (Ref. [@r7])                                                                  286                    315   103      231         231   47    0.80   0.67   0.95   0.010
  Overall                                                                                                                                                     0.97   0.87   1.08   0.585

*n* = 4,711 people with hypertension; *n* = 5,150 people without hypertension. OR, odds ratio; CI, confidence interval. *P* value for heterogeneity = 0.006.

*Studies 1*, *3*, *4*, and *5* correspond to the study numbers mentioned in the paper.

Studies with raw data.

###### 

Meta-analysis results for DBP stratified by PPARGC1A Gly482Ser genotypes

  Cohort                                                                                                                DBP, mmHg   ANOVA, *P* Value                                                                                                     
  --------------------------------------------------------------------------------------------- ------- ------- ------- ----------- ------------------ ------ ------------ ------ ------------ --------------------------------------- ------- --------- -------
  Danish whites                                                                                                                                                                                                                                          
      *Study 1* (Ref. [@r8])[\*](#t3fn1){ref-type="table-fn"}[†](#t3fn2){ref-type="table-fn"}   454     442     117     84.4        83.4--85.4         84.1   83.1--85.1   83.0   81.1--84.9   0.467                                   0.575   0.759     0.359
      *Study 3* (Ref. [@r8])[\*](#t3fn1){ref-type="table-fn"}[†](#t3fn2){ref-type="table-fn"}   63      69      25      78.7        75.9--81.5         76.8   74.1--79.5   77.4   73.0--81.8   0.601                                   0.053   0.659     0.776
      *Study 4* (Ref. [@r8])[\*](#t3fn1){ref-type="table-fn"}[†](#t3fn2){ref-type="table-fn"}   281     316     101     95.3        93.7--96.9         95.7   94.2--97.2   92.7   90.0--95.4   0.159                                   0.613   0.711     0.279
      *Study 5* (Ref. [@r8])[\*](#t3fn1){ref-type="table-fn"}[†](#t3fn2){ref-type="table-fn"}   212     195     65      76.7        75.4--78           75.7   74.4--77.0   78.7   76.4--81.0   0.080                                   0.463   0.971     0.467
  Pima Indians[†](#t3fn2){ref-type="table-fn"}                                                  735     318     35      67.9        67.1--68.7         68.5   67.2--69.8   70.5   66.6--74.4   0.363                                   0.924   0.593     0.504
  UK whites                                                                                                                                                                                                                                              
      MRC Ely[†](#t3fn2){ref-type="table-fn"}                                                   233     306     73      77.0        75.7--78.3         75.9   74.8--77.0   73.2   70.9--75.5   0.018                                   0.251   0.532     0.397
      CCCS cases[†](#t3fn2){ref-type="table-fn"}                                                175     176     43      86.3        84.8--87.8         85.1   83.6--86.6   85.8   82.7--88.9   0.541                                   0.236   0.214     0.327
      CCCS controls[†](#t3fn2){ref-type="table-fn"}                                             194     197     75      83.9        82.4--85.4         84.6   83.0--86.2   87.0   84.5--89.5   0.131                                   0.113   0.266     0.593
  French Canadians (Ref. [@r2])[†](#t3fn2){ref-type="table-fn"}                                 64      73      19      84.6        82.1--87.1         87.5   85.2--89.8   89.0   84.4--93.6   0.137                                   0.085   0.4       0.19
  EPIC                                                                                                                                                                                                                                                   
      Obese[†](#t3fn2){ref-type="table-fn"}                                                     364     339     96      86.3        85.2--87.4         86.1   85.0--87.2   86.0   83.9--88.1   0.973                                   0.051   0.188     0.854
      Cohort[†](#t3fn2){ref-type="table-fn"}                                                    762     789     201     81.9        81.2--82.6         82.0   81.3--82.7   82.5   81.1--83.9   0.805                                   0.878   0.59      0.858
  Danish whites (Ref. [@r4])[‡](#t3fn3){ref-type="table-fn"}                                    931     1,036   288     81.8        81.1--82.5         82.3   81.7--82.9   82.0   80.7--83.3   0.39                                                      
  Asian Indians                                                                                                                                                                                                                                          
      Controls (Ref. [@r3])[‡](#t3fn3){ref-type="table-fn"}                                     534     360     81      76.0        75.2--76.8         75.0   74.0--76.0   75.0   72.8--77.2   0.6                                                       
      Cases (Ref. [@r3])[‡](#t3fn3){ref-type="table-fn"}                                        303     212     52      79.0        77.8--80.2         77.0   75.5--78.5   75.0   72.3--77.7   0.007                                                     
  Slovenian whites                                                                                                                                                                                                                                       
      Cases (Ref. [@r5])[‡](#t3fn3){ref-type="table-fn"}                                        114     118     29      84.7        83--86.4           85.7   83.8--87.6   85.0   82.5--87.5   0.74                                                      
      Controls (Ref. [@r5])[‡](#t3fn3){ref-type="table-fn"}                                     14      15      1       83.8        78.1--89.5         84.8   78.5--91.1   84.0                0.7                                                       
  Overall                                                                                       5,433   4,961   1,301   80.3        80--80.6           81.5   81.2--81.8   82.1   81.5--82.7   0.651[§](#t3fn4){ref-type="table-fn"}   0.715   0.00004   0.953
  Standard error                                                                                                                                                                               0.005[§](#t3fn4){ref-type="table-fn"}                     
  Cohort heterogeneity *P*                                                                                                                                                                     0.021[§](#t3fn4){ref-type="table-fn"}                     
  Ethnicity heterogeneity *P*                                                                                                                                                                  0.414[§](#t3fn4){ref-type="table-fn"}                     
  Caucasian only                                                                                                                                                                                                                                         
      Overall                                                                                   3,861   4,071   1,133   83.4        83.0--83.7         83.3   83.0--83.7   83.3   82.7--83.9   0.659[§](#t3fn4){ref-type="table-fn"}   0.700   0.789     0.348
      Heterogeneity *P*                                                                                                                                                                        0.109[§](#t3fn4){ref-type="table-fn"}                     

*Studies 1*, *3*, *4*, and *5* correspond to the study numbers mentioned in the paper.

Studies with raw data. The main effect and interaction analyses are adjusted for age and sex.

Studies from published paper. Mean, SD, and ANOVA *P* values were obtained from published papers or from authors.

Based on 10,000 simulations. A random-effect generalized linear model is applied if *P* \< 0.05 for heterogeneity; otherwise, a fixed model is applied.

###### 

Meta-analysis results for SBP stratified by PPARGC1A Gly482Ser genotypes

  Cohort                                                                                                                SBP, mmHg   ANOVA, *P* Value                                                                                                         
  --------------------------------------------------------------------------------------------- ------- ------- ------- ----------- ------------------ ------- -------------- ------- -------------- --------------------------------------- ------- ------- -------
  Danish whites                                                                                                                                                                                                                                              
      *Study 1* (Ref. [@r8])[\*](#t4fn1){ref-type="table-fn"}[†](#t4fn2){ref-type="table-fn"}   454     442     117     133.9       132.3--135.5       133.3   131.7--134.9   129.6   126.5--132.7   0.055                                   0.189   0.571   0.891
      *Study 3* (Ref. [@r8])[\*](#t4fn1){ref-type="table-fn"}[†](#t4fn2){ref-type="table-fn"}   63      69      25      136.2       131.6--140.8       131.6   127.2--136     139.8   132.4--147.2   0.131                                   0.116   0.477   0.581
      *Study 4* (Ref. [@r8])[\*](#t4fn1){ref-type="table-fn"}[†](#t4fn2){ref-type="table-fn"}   281     316     101     157.5       154.9--160.1       160.0   157.6--162.4   154.9   150.6--159.2   0.101                                   0.106   0.988   0.574
      *Study 5* (Ref. [@r8])[\*](#t4fn1){ref-type="table-fn"}[†](#t4fn2){ref-type="table-fn"}   212     195     65      135.0       132.6--137.4       133.7   131.2--136.2   134.8   130.5--139.1   0.748                                   0.653   0.305   0.113
  Pima Indians[†](#t4fn2){ref-type="table-fn"}                                                  735     318     35      115.8       114.6--117         116.8   114.9--118.7   121.6   116--127.2     0.103                                   0.082   0.901   0.036
  UK whites                                                                                                                                                                                                                                                  
      MRC Ely[†](#t4fn2){ref-type="table-fn"}                                                   233     306     73      127.6       125.7--129.5       125.2   123.5--126.9   121.2   117.8--124.6   0.005                                   0.203   0.123   0.632
      CCCS cases[†](#t4fn2){ref-type="table-fn"}                                                175     176     43      138.4       135.9--140.9       137.4   134.9--139.9   141.4   136.3--146.5   0.197                                   0.031   0.336   0.439
      CCCS controls[†](#t4fn2){ref-type="table-fn"}                                             194     197     75      145.5       143.1--147.9       143.7   141.3--146.1   143.8   140--147.6     0.484                                   0.147   0.292   0.791
  French Canadians (Ref. [@r2])[†](#t4fn2){ref-type="table-fn"}                                 64      73      19      142.0       137.4--146.6       144.6   140.3--148.9   137.8   129.4--146.2   0.131                                   0.625   0.173   0.031
  EPIC                                                                                                                                                                                                                                                       
      Obese[†](#t4fn2){ref-type="table-fn"}                                                     364     339     96      138.8       137.2--140.4       141.0   139.3--142.7   139.1   135.9--142.3   0.183                                   0.043   0.015   0.695
      Cohort[†](#t4fn2){ref-type="table-fn"}                                                    762     789     201     134.1       133--135.2         134.0   132.9--135.1   134.4   132.2--136.6   0.947                                   0.804   0.556   0.654
  Danish whites (Ref. [@r4])[‡](#t4fn3){ref-type="table-fn"}                                    931     1,036   288     128.4       127.2--129.6       129.6   128.4--130.8   129.5   127.1--131.9   0.09                                                    
  Asian Indians                                                                                                                                                                                                                                              
      Controls (Ref. [@r3])[‡](#t4fn3){ref-type="table-fn"}                                     534     360     81      120.0       118.6--121.4       121.0   119.2--122.8   119.0   115.7--122.3   0.42                                                    
      Cases (Ref. [@r3])[‡](#t4fn3){ref-type="table-fn"}                                        303     212     52      130.0       127.9--132.1       126.0   123.8--128.2   124.0   119.7--128.3   0.006                                                   
  Slovenian whites                                                                                                                                                                                                                                           
      Cases (Ref. [@r5])[‡](#t4fn3){ref-type="table-fn"}                                        114     118     29      144.6       140.5--148.7       146.5   142.5--150.5   141.0   132.8--149.2   0.45                                                    
      Controls (Ref. [@r5])[‡](#t4fn3){ref-type="table-fn"}                                     14      15      1       143.8       133.1--154.5       145.2   133.1--157.3   142.0                  0.6                                                     
  Overall                                                                                       5,433   4,961   1,301   131.0       130.5--131.5       133.1   132.6--133.6   133.5   132.5--134.5   0.409[§](#t4fn4){ref-type="table-fn"}   0.966   0.026   0.202
  Standard error                                                                                                                                                                                     0.006[§](#t4fn4){ref-type="table-fn"}                   
  Cohort heterogeneity *P*                                                                                                                                                                           0.003[§](#t4fn4){ref-type="table-fn"}                   
  Ethnicity heterogeneity *P*                                                                                                                                                                        0.649[§](#t4fn4){ref-type="table-fn"}                   
  Caucasian only                                                                                                                                                                                                                                             
      Overall                                                                                   3,861   4,071   1,133   135.6       135.0--136.1       135.8   135.2--136.3   135.3   134.2--136.4   0.419[§](#t4fn4){ref-type="table-fn"}   0.960   0.804   0.138
      Heterogeneity *P*                                                                                                                                                                              0.035[§](#t4fn4){ref-type="table-fn"}                   

*Studies 1*, *3*, *4*, and *5* correspond to the study numbers mentioned in the paper.

Studies with raw data. The main effect and interaction analyses are adjusted for age and sex.

Studies from published paper. Mean, SD, and ANOVA *P* values were obtained from published papers or from authors.

Based on 10,000 simulations. A random-effect generalized linear model is applied if *P* \< 0.05 for heterogeneity; otherwise, a fixed model is applied.
